Business context and reporting period
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology biotechnology company with no revenue. This Form 10-Q covers the fiscal quarter and nine months ended April 30, 2024; amounts are in U.S. dollars. Its lead program, Bria-IMT with retifanlimab, is in a pivotal Phase 3 study for advanced metastatic breast cancer and has FDA Fast Track designation. The filing describes Bria-OTS and a soluble CD80 therapeutic as other development programs.
Financial results and liquidity
| Metric | Three months ended April 30, 2024 | Nine months ended April 30, 2024 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development | $7.66 million | $22.77 million |
| General and administrative | $1.57 million | $4.79 million |
| Total operating expenses / operating loss | $9.23 million | $27.56 million |
| Net income (loss) attributable to BriaCell | $1.72 million / $0.11 per share | $(3.58) million / $(0.22) per share |
| Net cash used in operating activities | Not presented for the quarter | $20.09 million |
The quarterly profit reflects a $10.95 million gain from a decline in the fair value of warrant liabilities, rather than operating income. For the nine months, the $23.66 million warrant fair-value gain substantially offset operating losses. The filing provides no meaningful operating margin because BriaCell reported no revenue.
At April 30, cash and cash equivalents were $935,694, down from $21.25 million at July 31, 2023. Current assets were $5.53 million and current liabilities $6.76 million, yielding negative working capital of $1.23 million, versus positive working capital of $25.15 million at July 31. Trade payables rose to $6.42 million from $1.12 million. The company reported no interest-bearing debt; its $5.68 million warrant liability is a fair-value liability, not conventional borrowing. Total assets were $6.20 million and accumulated deficit was $84.23 million.
Material changes versus the prior comparable period
- Quarterly R&D expense rose to $7.66 million from $3.86 million; nine-month R&D rose to $22.77 million from $10.17 million. Management cited longer patient participation, Phase 3 start-up and clinical-trial costs, and development preparation for Bria-OTS.
- Quarterly G&A declined to $1.57 million from $1.82 million; nine-month G&A declined to $4.79 million from $5.40 million, primarily from lower professional fees and insurance costs.
- Warrant fair-value movements swung from a $2.97 million loss in the prior-year nine-month period to a $23.66 million gain in the current period. Management attributed the change mainly to a lower share price and shorter warrant life. This noncash valuation movement materially affects reported earnings.
- Cash used in operations increased to $20.09 million from $12.83 million for the nine-month comparison. No shares were issued during the nine months ended April 30, 2024.
Outlook, risks, and notable events
Management states that substantial operating losses and negative operating cash flows are expected to continue. The filing says uncertainty about raising capital casts significant doubt on the company’s ability to continue as a going concern. Management plans to seek additional financing, reduce spending on certain non-core activities, and prioritize the Phase 3 Bria-IMT study; it also notes that directors and officers agreed to defer compensation beginning March 1, 2024. There is no assurance that further financing will be available or sufficient. No specific financial guidance or cash-runway estimate is provided.
The Phase 3 study was initiated October 3, 2023. The filing describes planned enrollment of 177 patients in the Bria-IMT combination arm, 177 in physician’s-choice treatment, and 50 in a Bria-IMT-alone group; overall survival is the primary endpoint for the comparison. Successful completion and regulatory review could support a future biologics license application, but are not assured.
On May 17, 2024, after quarter-end, BriaCell completed a registered direct offering for approximately $5.0 million gross proceeds, before fees and expenses, involving 2,402,935 common shares or pre-funded warrants and warrants for up to the same number of shares. The warrants have a $2.11 exercise price and become exercisable six months after issuance. This provides additional capital but carries potential dilution. In August 2023, the company spun out certain pipeline assets to BriaPro, in which BriaCell retained approximately two-thirds ownership. BriaCell accounts for its 51.2% interest in BC Therapeutics using the equity method because it says it does not control the investee.
Other disclosed commitments include office and lab space costing approximately $36,000 per month through August 31, 2024, and up to $241,164 payable to BriaPro upon specified warrant exercises. The filing reports no legal proceedings, material changes to previously disclosed risk factors, or material changes in internal control; management concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Available cash, current payables, and the company’s financing needs following the May 2024 offering; the filing identifies substantial doubt about going concern.
- Offering costs, actual shares versus pre-funded warrants issued, and the resulting current and fully diluted share count.
- Phase 3 enrollment, spending, timelines, and clinical progress, together with the risks inherent in trial outcomes and regulatory review.
- The effect of warrant-liability remeasurement on reported earnings and the potential dilution from outstanding warrants and options.
- The filing lists 15,981,726 shares outstanding at April 30, while its cover reports 18,284,661 shares outstanding as of June 14; verify the intervening issuance and share-count reconciliation.